Novel way to block the death of nerve cells in MND

Scientists have found a novel way to block the transportation of mutant RNA and subsequent production of toxic repeat proteins which lead to the death of nerve cells in the most common subtypes of motor neurone disease (MND) and frontotemporal dementia (FTD).

The new study, conducted by researchers at the University of Sheffield's Institute of Translational Neuroscience (SITraN), also showed that using a peptide to stop the transport of mutant repeated RNA molecules and production of toxic repeat proteins actually increases the survival of C9ORF72 nerve cells - protecting them against neurodegeneration.

The Sheffield team previously discovered the abnormal transportation of the rogue RNAs copied from the C9ORF72 gene - known to be the most frequent cause of MND and FTD - is caused by excessive stickiness of a cell transporter named SRSF1.

Instead of using conventional drugs, which are inefficient in disrupting the stickiness of the SRSF1 protein, or invasive therapies to edit or modulate the activity of defective genes, the new study found that a small peptide incorporating a cell-penetrating module can stick to SRSF1 and effectively block the transportation of the rogue repeat RNA.

The peptide is composed of a short chain of amino acids or bricks found within our cells and tissues in the body.

Interestingly, the findings, published in the journal Science Translational Medicine also suggest the peptide could be given to MND and FTD patients orally in a non-invasive manner - for example through a nasal spray which could be developed to enter the brain.

This groundbreaking concept of using peptides to block the effects of the damaging repeat expanded RNA and toxic repeat proteins could transform how some neurodegenerative conditions which currently have no cure are treated.

When we tested our innovative approach by adding the peptide to the food eaten by fruit flies not only did the peptides block the damaging mutations which cause MND and FTD from being transported to the cell's nucleus, we actually saw an improvement in their neurofunction. This means the peptide is effectively blocking the progression of the neurodegenerative condition and also helping to restore the function to the affected nerve cells."

Guillaume Hautbergue, Study Lead and Professor, Translational RNA Biology, University of Sheffield

"This concept of using peptides to block destructive mutations unlocks such an exciting and innovative treatment pathway which until now has not been explored by scientists.

"MND and FTD are devastating diseases which currently have no cure. This is a promising alternative to conventional small molecule drugs which are often limited by poor penetration of the blood-brain barrier."

FTD occurs when nerve cells in the frontal and temporal lobes of the brain are lost, causing the lobes to shrink. FTD most commonly affects people aged 45-65 and can affect behaviour, personality, language and movement. There is no cure for FTD, and no treatments available to slow or stop the progression of the disease.

MND is a debilitating condition that destroys the cells that control movement, leaving sufferers unable to move, walk, talk and eventually breathe. Treatments are very limited and there is no cure. Most patients with the disease are only expected to live two to five years after diagnosis. This study was made possible thanks to donated tissue samples from the skin of MND patients which were reprogrammed into nerve cells.

Dr Brian Dickie, Director of Research at the MND Association, said: "These findings from a world leading research team in Sheffield demonstrate the importance of funding fundamental 'discovery' science. This work has provided important evidence in support of a completely new strategy to treat the most common inherited cause of both MND and FTD, with the ultimate goal of developing effective therapies for these devastating diseases."

It is hoped the innovative research, conducted in collaboration with multiple labs in SITraN and with the groups of Dr Alexander Whitworth (University of Cambridge), Dr Cyril Dominguez (University of Leicester), Professor Frédéric Allain (ETH Zurich) and funded by the MND Association and the UKRI BBSRC and MRC councils will transform the future of clinical trials for the most common forms of MND and FTD within the next few years.

Journal reference:

Castelli, L. M., et al. (2023) A cell-penetrant peptide blocking C9ORF72-repeat RNA nuclear export reduces the neurotoxic effects of dipeptide repeat proteins. Science Translational Medicine.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists Pinpoint Gene Linked to Neuronal Susceptibility in Alzheimer’s Disease